21:13 PM

Study Finds Reducing BMI Could Achieve $461 Million in Economic Benefit Over 20 Years for Sample Group of Isagenix Customers

ASU’s Seidman Research Institute Study Shows Economic Savings and Increased Workforce Productivity

Body mass index (BMI) reductions among a sample group of 12,561 Isagenix International customers could save the U.S. economy $461 million over 20 years due to avoided medical treatment costs and retained workforce productivity gains linked to 20 diseases,1 according to a recent study. The L. William Seidman Research Institute, which serves as a connection between business communities and the W. P. Carey School of Business at Arizona State University, conducted the study for Isagenix, a global health and wellness company providing nutrition and lifestyle solutions.

Using two distinct approaches to identify the economic impact of reduced BMI, an estimate of body fat based on height and weight, “The Economic Impact of Weight Loss” study estimates the potential cost savings associated with sustained weight loss for four distinct groups:

  • A sample of 12,561 Isagenix customers who self-reported their weight loss to the company.
  • A peer-reviewed published clinical trial of 40 men and women who used Isagenix products to support weight loss.
  • An assumed Isagenix U.S. customer base of 500,000 who are presumably overweight or obese.2
  • Members of the U.S. population who are overweight or obese. 2

“Our study shows that reducing BMI could meaningfully decrease the negative economic impacts associated with diseases linked to being overweight or obese,” said Dennis Hoffman, Ph.D., director of the L. William Seidman Research Institute. “If more people achieved the same reduced BMI as the participants of the study who used Isagenix to reduce their BMI, the economy – including employers – could reap significant benefits.”

Isagenix customers achieve BMI reductions in part by using the company’s weight wellness solutions, including the IsaLean™ Shake, a meal replacement shake that supports efforts to burn and lose unwanted fat, and Cleanse for Life®, which helps nourish the body’s natural detoxifications systems.

Seidman’s key study findings3 include:

  • Approximately 20 percent of the costs to the U.S. economy resulting from 20 weight-related diseases identified by Milken Institute’s 2016 study, “Weighing Down America: The Health and Economic Impact of Obesity,” could be avoided if BMI reductions similar to those reported by the sample of 12,561 Isagenix customers took place across the nation’s overweight and obese populations. Milken estimated the total cost to treat health conditions related to obesity and obesity’s impact on attendance and work productivity exceeds $1.4 trillion annually.
  • The total estimated savings to the U.S. economy attributed to the sample group of 12,561 Isagenix customers could be $461 million ($36,700 per person) over 20 years due to potential reduced incidence of 20 diseases, five of which are chronic conditions including asthma, back pain, diabetes, hypertension, and osteoarthritis. The study estimates more than $18 billion in savings is possible over 20 years if the same results were achieved by an assumed Isagenix U.S. customer population of 500,000, and trillions of dollars in savings could be achieved over 20 years for the U.S. population.
  • Due to BMI reductions reported by the sample of 12,561 Isagenix customers, those customers are projected to avoid losing a combined 57,320 days annually to poor health. This equates to saving approximately 4.5 days per year per customer. For those in the workforce, saved days represent wages retained or sick time not claimed, which provides value for the employee, as well as for the employer and the overall economy, through retained productive output.
  • If all U.S. Isagenix customers were to achieve the successes reported by the sample of 12,561 Isagenix customers, the study projects approximately $918 million in total retained earnings and treatment savings annually.

Isagenix Chief Executive Officer Travis Ogden said he values how “The Economic Impact of Weight Loss” study highlights the benefits of Isagenix empowering customers to live their best lives.

“By providing science-backed solutions that inspire people to transform their health and their lives, Isagenix not only helps address the serious health issues associated with being overweight but also positively impacts the economy,” Ogden said. “We look forward to magnifying these efforts as we continue expanding around the world, bringing our high-quality products to new markets and customers.”

To read “The Economic Impact of Weight Loss” study, visit the Resources section of the Isagenix Newsroom. For key stats from the study and a quick look at how Isagenix customers have transformed their lives, view the infographic.

To learn more about Isagenix, visit our newsroom at, like us on Facebook at, and follow us on Twitter and Instagram at @Isagenix.

1Asthma, Alzheimer’s, breast cancer, chronic back pain, colorectal cancer, congestive heart failure, coronary heart disease, diabetes, end stage renal disease, endometrial cancer, esophageal adenocarcinoma, gallbladder cancer, gallbladder disease, gastric cardia adenocarcinoma, hypertension, osteoarthritis, ovarian cancer, pancreatic cancer, renal cancer, and stroke.

2The Isagenix U.S. customer base and members of the U.S. population who are overweight or obese are simulated to have the same overweight and obese proportions and ages as the sample of 12,561 Isagenix customers.

3The study assumes an average age of 45, and when calculating the 20-year savings and benefits, assumes individuals work to the age of 65 while maintaining the weight loss/BMI reduction.

About Isagenix International

Established in 2002, Isagenix International believes that everyone deserves to experience a healthy, joyful, and abundant life. The global wellbeing company artfully crafts more than 175 effective products and offers a supportive community for its more than 550,000 customers worldwide. Isagenix shares its products through a network of independent distributors in 26 markets: the United States, Canada, Puerto Rico, Hong Kong, Australia, New Zealand, Taiwan, Mexico, the United Kingdom, Ireland, the Netherlands, Belgium, Spain, South Korea, Austria, Denmark, Finland, France, Germany, Italy, Japan, Norway, Poland, Portugal, Sweden, and Switzerland. The private family-owned company has its world headquarters in Gilbert, Arizona. For more information, visit​.